Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer

Norma B. Bulamu, Christine Mpundu-Kaambwa, Michael O'Callaghan, Billingsley Kaambwa

Research output: Contribution to journal › Article › peer-review

54 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer'. Together they form a unique fingerprint.

Nursing and Health Professions

Agricultural and Biological Sciences

Pharmacology, Toxicology and Pharmaceutical Science